

Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019

<https://marketpublishers.com/r/T3AF227AFFDFEN.html>

Date: December 2019

Pages: 85

Price: US\$ 3,500.00 (Single User License)

ID: T3AF227AFFDFEN

Abstracts

Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019

SUMMARY

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration and immune response. It phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Respiratory and Toxicology which include indications Breast Cancer, Colon Cancer, High-Grade Glioma, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis,

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Arrhythmias, Asthma, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Fallopian Tube Cancer, Fibrosarcoma, Gallbladder Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leiomyosarcoma, Liposarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Mild Cognitive Impairment, Myocardial Infarction, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Psoriasis, Radiation Injury, Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma, Renal Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Thyroid Cancer and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Athenex Inc

Pfizer Inc

Pulmatrix Inc

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Drug Profiles

apatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eCF-506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KX-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PUR-1800 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit C Src Kinase for Colon Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CSK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirbanibulin mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UM-164 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin

Ointment

Sep 29, 2019: Elevar announces results from the ANGEL trial, a study of Monotherapy Rivoceranib (Apatinib) in Late-stage Gastric Cancer patients

Sep 11, 2019: Athenex announces initiation of phase I clinical study in china of KX2-36 oral by partner Guangzhou Xiangxue pharmaceutical

Aug 23, 2019: HLB wins FDA nod for P2 trial on rivoceranib in adenoid cystic carcinoma

Aug 06, 2019: HLB to seek pre-NDA meeting with FDA for rivoceranib

Jun 27, 2019: LSK BioPharma announces preliminary review of top-line results from ANGEL Study

Jun 06, 2019: Athenex and PharmaEssentia announce positive early signals of clinical activity of KX2-391 (INN: tirbanibulin) in patients with Psoriasis

Apr 08, 2019: LSK BioPharma and Jiangsu Hengrui Medicine announce FDA clearance to initiate a phase 3 clinical trial in advanced Hepatocellular Carcinoma

Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting

Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting

Feb 12, 2019: LSKB Announces that the ANGEL Study Has Reached its Primary Completion Date

Feb 12, 2019: Pulmatrix receives US Patent for Inhaled Narrow Spectrum Kinase Inhibitor PUR1800

Feb 04, 2019: Athenex announces late-breaking oral presentation of KX2-391 ointment in two phase III studies at the American Academy of Dermatology Annual Meeting

Oct 29, 2018: LSKB announces completion of enrollment for the ANGEL Study of Rivoceranib (Apatinib) in Gastric Cancer

Sep 17, 2018: Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Advenchen Laboratories LLC, H2 2019
Pipeline by Athenex Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Pulmatrix Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Advenchen Laboratories LLC

Athenex Inc

Pfizer Inc

Pulmatrix Inc

I would like to order

Product name: Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/T3AF227AFFDFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T3AF227AFFDFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970